Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2024-02-08 00:00:00 ET · period of report 2024-02-06 · accession 0000875320-24-000016 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2024-02-08 | 2024-02-06+ | VRTX | Ambrose Kristen | SVP, CAO | A - Grant | $0.00 | +4,803 | 9,788 | +96% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-07 | A | A | 1,853 | $0.00 | 11,641 | D | — | — | (F2) Restricted stock unit award that vests in installments beginning on 02/17/2025. |
| 2 | Common | Common Stock | 2024-02-06 | A | A | 2,950 | $0.00 | 9,788 | D | — | — | (F1) Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/06/2024 and the shares will vest in installments beginning on 02/10/2024. |